Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study

被引:1
|
作者
Cong, Duanduan [1 ]
Song, Jie [2 ]
Liu, Yue [1 ]
Tan, Yan [2 ]
Xue, Wei [1 ]
Liu, Xiaohui [1 ]
Qi, Wenyuan [1 ]
Lu, Jun [2 ]
Yuan, Xiaojuan [3 ]
Zhou, Yongchun [3 ]
Hui, Ai-Min [2 ]
Li, Kexin [1 ]
机构
[1] Chinese Acad Med Sci, Clin Trial Ctr, Beijing Hosp, Natl Ctr Gerontol,Inst Geriatr Med,Assessment Cli, 1 Dahua Rd, Beijing 100005, Peoples R China
[2] Shanghai Fosun Pharmaceut Dev Co Ltd, Clin Res Dept, Shanghai 200000, Peoples R China
[3] Wanbang Biopharmaceut Co Ltd, Xuzhou, Jiangsu, Peoples R China
关键词
Clinical trial; COMT inhibitor; Ethnicity; Opicapone; Pharmacodynamics; Pharmacokinetics; Tolerability; CATECHOL-O-METHYLTRANSFERASE; PARKINSONS-DISEASE; MOTOR FLUCTUATIONS; LEVODOPA; INHIBITORS; DISCOVERY; THERAPY; ADJUNCT; LIVER;
D O I
10.1007/s40120-021-00314-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction This study evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of opicapone (OPC) in healthy Chinese and Caucasian subjects. Methods In this open-label, single-center, phase 1 study, eligible Chinese subjects received one of three OPC doses (25, 50, or 100 mg), and Caucasian subjects received either 25 or 50 mg of OPC. All subjects were administered a single dose of OPC, whereas subjects in the 50-mg OPC group continued to receive once-daily doses of 50 mg OPC for 10 days. The primary endpoint was to evaluate and compare the plasma concentrations and PK parameters of OPC and its main metabolite, and erythrocyte-soluble catechol-O-methyltransferase (S-COMT) activity in Chinese subjects with that of Caucasian subjects. The secondary endpoint was to evaluate the safety of OPC in Chinese subjects. The estimated results for geometric mean ratios (GMRs) were evaluated with the standard bioequivalence (BE) limits between 80% and 125% to evaluate the ethnic differences. All statistical analyses were performed using SAS version 9.4. Results In total, 70 subjects (45 Chinese, 25 Caucasian) were enrolled; the majority of them were male (85.7%). The plasma exposure of both OPC and BIA 9-1103 increased in an approximately dose-proportional manner in both populations. Maximum S-COMT inhibition ranged from 79% to 95% after a single dose and was about 94% after a 10-day once-daily regimen in both populations. The point estimates of GMRs (Chinese/Caucasian) and 90% CI, except C-max in 25-mg and 50-mg OPC groups, for PK and PD parameters were within 80% to 125%. Furthermore, no new risks or safety concerns associated with OPC were identified, indicating a tolerable safety profile in healthy Chinese subjects. Conclusion Ethnicity had no significant impact on PK and PD parameters after single or multiple doses of OPC, and OPC was safe and tolerable in healthy Chinese subjects.
引用
收藏
页码:283 / 301
页数:19
相关论文
共 50 条
  • [21] Pharmacokinetics and tolerability of intravenous posaconazole in healthy Chinese volunteers: a randomized, open-label and single-dose study
    Ji, Wei
    Zhao, Hengli
    Yang, Shaomei
    Wen, Qing
    He, Kun
    PHARMAZIE, 2020, 75 (10): : 491 - 493
  • [22] A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
    Trivedi, Ashit
    Mather, Omar
    Vega, Silvia
    Hutton, Shauna
    Hellawell, Jennifer
    Lee, Edward
    DRUGS IN R&D, 2022, 22 (02) : 141 - 146
  • [23] Pharmacokinetics, Pharmacodynamics, Tolerability and Safety of Single Doses of Bivalirudin in Healthy Chinese Subjects
    Zhang, Dongmei
    Wang, Zining
    Zhao, Xia
    Lu, Wei
    Gu, Jingkai
    Cui, Yimin
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2011, 34 (12) : 1841 - 1848
  • [24] A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
    Ashit Trivedi
    Omar Mather
    Silvia Vega
    Shauna Hutton
    Jennifer Hellawell
    Edward Lee
    Drugs in R&D, 2022, 22 : 141 - 146
  • [25] Pharmacokinetics and Tolerability of Single and Multiple Doses of Ticagrelor in Healthy Chinese Subjects An Open-Label, Sequential, Two-Cohort, Single-Centre Study
    Li, Haiyan
    Butler, Kathleen
    Yang, Li
    Yang, Zhenghua
    Teng, Renli
    CLINICAL DRUG INVESTIGATION, 2012, 32 (02) : 87 - 97
  • [26] Pharmacokinetics and tolerability of cinitapride in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study
    Zhang, Xiong
    Wang, Ying
    Cheng, Junlin
    Hu, Yunfang
    Liu, Jianghui
    Chen, Jing
    Yang, Xingye
    Fan, Hongwei
    XENOBIOTICA, 2019, 49 (03) : 313 - 321
  • [27] Pharmacokinetics of Single and Multiple Doses of Omega-3 Carboxylic Acids in Healthy Chinese Subjects: A Phase I, Open-Label Study
    Jing, Shan
    Zhang, Zhenxian
    Chen, Xiaowen
    Miao, Rui
    Nilsson, Catarina
    Lin, Yang
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (08): : 985 - 994
  • [28] Single- and multiple-dose pharmacokinetics of genistein capsules in healthy Chinese subjects: A phase I, randomized, open-label study
    Zeng, Xing
    Feng, Yi
    Yang, Liu
    Huang, Yu
    Zhou, Dan
    Sun, Jing
    Liu, Yiming
    Deng, Yuanhui
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2008, 69 (04): : 318 - 333
  • [29] Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects
    Almeida, Luis
    Rocha, Jose Francisco
    Falca, Amilcar
    Nuno Palma, P.
    Loureiro, Ana I.
    Pinto, Roberto
    Bonifacio, Maria Joao
    Wright, Lyndon C.
    Nunes, Teresa
    Soares-da-Silva, Patricio
    CLINICAL PHARMACOKINETICS, 2013, 52 (02) : 139 - 151
  • [30] Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study
    Sohn, Winnie
    Winkle, Peter
    Neutel, Joel
    Wu, You
    Jabari, Freeman
    Terrio, Caitlin
    Varrieur, Tracy
    Wang, Jingying
    Hellawell, Jennifer
    CLINICAL THERAPEUTICS, 2022, 44 (09) : 1237 - 1247